#USA #San Jose #Intalight #DREAM OCT #CE Mark

Intalight™ Achieves CE Mark for DREAM OCT™ Imaging System

In an exciting development for the field of ophthalmology, Intalight™, a pioneering company specializing in advanced ophthalmic technologies, has successfully attained the CE mark for its revolutionary imaging platform, DREAM OCT™. This achievement opens the door for commercial use within the European Union, allowing healthcare professionals to utilize state-of-the-art diagnostic tools for improved patient outcomes.

What is the DREAM OCT™?

DREAM OCT™, short for Depth Imaging, exceptional scanning speed, wide range, accurate results, and multimodal imaging features, showcases exceptional quality in Optical Coherence Tomography (OCT) imaging. The platform is designed to elevate clinical imaging standards, making it a valuable asset for ophthalmologists across Europe.

The certification, announced in San Jose, California, and Shanghai, is a significant milestone for both Intalight and the medical community. According to Shawn Peng, the founder, and chairman of Intalight™, this approval enables them to offer cutting-edge technology to ophthalmologists, ultimately resulting in better care for their patients.

Key Features of DREAM OCT™

One of the standout features of DREAM OCT™ is its capability to cover ultra-wide fields of view in a single scan, providing a 130-degree image through Optical Coherence Tomography Angiography (OCTA). The super-depth imaging technology allows for detailed visualization of the retina and choroid, as well as extensive portions of the vitreous space. Moreover, the anterior segment scanning capabilities extend to 16.2 mm in air, enabling comprehensive scans from the cornea to the anterior vitreous in a brief timeframe.

The longer wavelength used in DREAM OCT™ is particularly beneficial, allowing for excellent penetration through opacities that may exist in the lens or vitreous humor, which can complicate imaging efforts in a clinical setting.

The Growing Demand for Advanced Imaging Solutions

As stated by Bing Li, the CEO and co-founder of Intalight™, practitioners have expressed a pressing need for imaging solutions that meet the demands of speed, precision, and depth in their clinical practices. DREAM OCT™ not only meets these challenges, but provides a comprehensive suite of imaging modalities designed for the most demanding clinical and research applications involving the retina.

Currently, more than 160 peer-reviewed studies are utilizing insights from the DREAM OCT™ device, underscoring its importance in the ophthalmic research community.

Future Prospects

Intalight's recent achievement in obtaining the CE mark marks a significant leap toward expanding its reach into the United States market, where it hopes to gain FDA approval soon. Joe Garibaldi, the Chief Commercial Officer of Intalight™, expressed excitement over this prospect, stating that the company is eager to start delivering this innovative solution to healthcare providers in the U.S.

As a clinically verified leader in the field of ultra-widefield OCTA, Intalight collaborates with esteemed scientific institutions and private eye clinics across the U.S., Europe, and Asia. The company began its journey with a mission to develop the most advanced ophthalmic technologies, and with the introduction of DREAM OCT™, they are well on their way to achieving that goal.

To learn more about Intalight™ and the DREAM OCT™ imaging system, visit their website at intalight.com and follow them on LinkedIn and Facebook for the latest updates.